title: Exploring the population-level impact of MenB vaccination via modeling: Potential for serogroup replacement.
abstract: Various meningococcal conjugate vaccines exist against serogroups A, C, W and Y. A new protein-based vaccine targeting serogroup B (MenB) is also now available. The potential of such vaccines to drive serogroup replacement is considered a possible public health concern when implementing nationwide routine immunization programmes. The aim of this work was to investigate if and how serogroup replacement may occur following widespread vaccination with a MenB vaccine that may protect against carriage. To that end, we built a dynamic transmission model with age and serogroup stratification, focusing on European settings where most invasive meningococcal disease (IMD) cases are caused by serogroups B and C. For illustration purposes, the model was employed in 2 such settings: UK (England and Wales) and Czech Republic. Preliminary model-based projections suggest that, under strong serogroup competition for colonization, vaccine-induced serogroup replacement may occur even with a relatively low vaccine efficacy against serogroup B carriage (e.g., 20%), with potential subsequent increase in serogroup C IMD. The magnitude and speed of the model-projected serogroup C IMD increase depend on the MenB vaccination strategy, vaccine efficacy against carriage and the extent of any potential cross-protection against other serogroups. These analyses are neither exhaustive nor definitive, and focused on simulating potential population-level trends in IMD post-vaccination, under certain assumptions. Due to present inherent limitations and uncertainties, this study has limited quantitative value and is best regarded as an explorative qualitative modeling approach, to complement and challenge the current status quo, and suggest areas where collecting additional data may be essential.
authors: a GSK Vaccines; Vaccine Value & Health Science Epidemiology ; Philadelphia , PA USA.|c Present affiliation: GSK Vaccines; Health Outcomes ; Philadelphia , PA USA.
authors: Cosmina
authors: C
authors: Hogea
authors: b GSK Vaccines; Vaccine Value & Health Science Epidemiology ; Wavre , Belgium.
authors: Thierry
authors: T
authors: Van Effelterre
authors: b GSK Vaccines; Vaccine Value & Health Science Epidemiology ; Wavre , Belgium.
authors: Andrew
authors: A
authors: Vyse
mesh_terms: D000293:Adolescent; D000907:Antibodies, Bacterial / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D056738:Cross Protection / Q000276:immunology; D018153:Czech Republic; D006801:Humans; D007223:Infant; D032541:Mass Vaccination; D008585:Meningitis, Meningococcal / Q000382:microbiology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000276:immunology*; D008962:Models, Theoretical; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology*; D038542:Neisseria meningitidis, Serogroup C / Q000276:immunology*; D006113:United Kingdom; D014611:Vaccination
chemical_list: D000907:Antibodies, Bacterial; D022401:Meningococcal Vaccines
keywords: dynamic transmission model; invasive meningococcal disease; mathematical modeling; serogroup B meningococcal vaccine; serogroup replacement